Stefan Engst
56 works · 2,948 citations · h-index 19
Top works
- Cabozantinib (XL184), a Novel MET and VEGFR2 Inhibitor, Simultaneously Suppresses Metastasis, Angiogenesis, and Tumor Growth
- Inhibition of Tumor Cell Growth, Invasion, and Metastasis by EXEL-2880 (XL880, GSK1363089), a Novel Inhibitor of HGF and VEGF Receptor Tyrosine Kinases
- Intermittent Administration of MEK Inhibitor GDC-0973 plus PI3K Inhibitor GDC-0941 Triggers Robust Apoptosis and Tumor Growth Inhibition
- Molecular characterization of medium-chain acyl-CoA dehydrogenase (MCAD) deficiency: identification of a lys329 to glu mutation in the MCAD gene, and expression of inactive mutant enzyme protein in E. coli
- Novel Carboxamide-Based Allosteric MEK Inhibitors: Discovery and Optimization Efforts toward XL518 (GDC-0973)
- Characterization of wild-type and an active site mutant of human medium chain acyl-CoA dehydrogenase after expression in Escherichia coli.
- In Vitro and In Vivo Activity of Cabozantinib (XL184), an Inhibitor of RET, MET, and VEGFR2, in a Model of Medullary Thyroid Cancer
- Alternative Routes for Entry of HgX2 into the Active Site of Mercuric Ion Reductase Depend on the Nature of the X Ligands
- Discovery of XL413, a potent and selective CDC7 inhibitor
- Supraphysiological levels of GDF11 induce striated muscle atrophy
- Substrate Activation by Acyl-CoA Dehydrogenases: Transition-State Stabilization and pKs of Involved Functional Groups
- Mechanism of Activation of Acyl-CoA Substrates by Medium Chain Acyl-CoA Dehydrogenase: Interaction of the Thioester Carbonyl with the Flavin Adenine Dinucleotide Ribityl Side Chain
- The design, synthesis, and biological evaluation of PIM kinase inhibitors
- Biochemical Characterization of Purified, Human Recombinant Lys304→Glu Medium‐Chain Acyl‐Coa Dehydrogenase Containing the Common Disease‐Causing Mutation and Comparison with the Normal Enzyme
- Alpha, beta-dehydrogenation by acyl-CoA dehydrogenases: role of functional groups at the active center.
- Rapid Reduction of Hg(II) by Mercuric Ion Reductase Does Not Require the Conserved C-Terminal Cysteine Pair Using HgBr2 as the Substrate
- Design and evaluation of a series of pyrazolopyrimidines as p70S6K inhibitors
- Pyrazolopyrimidines as dual Akt/p70S6K inhibitors
- SAR and in vivo evaluation of 4-aryl-2-aminoalkylpyrimidines as potent and selective Janus kinase 2 (JAK2) inhibitors
- Properties of p-Cresol Methylhydroxylase Flavoprotein Overproduced by Escherichia coli